Fate Therapeutics to Webcast Q1 2024 Financial Results and Updates

Fate Therapeutics, Inc., a biopharmaceutical company focused on developing innovative cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), is set to host a conference call and webcast on Thursday, May 9, 2024, at 5:00 PM ET. During the event, the company will discuss its financial results for the first quarter of 2024 and provide updates on its operations, with a particular emphasis on its FT819 and FT522 programs. These programs, which target autoimmune diseases, will also be showcased on the same day at the American Society of Gene and Cell Therapy's 27th Annual Meeting.

Fate Therapeutics specializes in using its proprietary iPSC product platform to develop off-the-shelf cellular therapies aimed at treating cancer and autoimmune diseases. The company has established a significant position in the field through its development of multiplexed-engineered master iPSC lines and its expertise in the clinical development of these cell products.

The company's pipeline includes a range of iPSC-derived products, notably natural killer (NK) cells and T-cells. These products are designed with selective features and novel synthetic controls to enhance their function. The aim is to offer multiple therapeutic mechanisms to patients, improving treatment outcomes for those suffering from cancer and autoimmune conditions.

Fate Therapeutics operates out of its headquarters in San Diego, California, and continues to focus on advancing its innovative treatments through clinical trials and development efforts.

To participate in the upcoming conference call, domestic callers can dial (833) 630-1956, while international participants should use (412) 317-1837. The live webcast will be accessible through the "Events & Presentations" section of the Investors page on the company's website. An archived version of the webcast will be available approximately two hours after the event for those who cannot attend the live session.

In summary, Fate Therapeutics remains committed to pioneering new cellular therapies derived from iPSCs to offer new hope for patients with serious health conditions such as cancer and autoimmune diseases. Their upcoming conference call will provide valuable insights into the progress and future direction of the company's key programs, FT819 and FT522.